

INTRODUCTION .....	XIV
STUDY GOALS AND OBJECTIVES.....	XIV
REASONS FOR DOING THIS STUDY .....	XIV
CONTRIBUTIONS TO THE STUDY AND FOR WHOM.....	XIV
SCOPE AND FORMAT .....	XV
METHODOLOGY .....	XV
INFORMATION SOURCES.....	XV
AUTHOR'S CREDENTIALS .....	XVI
RELATED BCC REPORTS .....	XVI
BCC ONLINE SERVICES.....	XVI
DISCLAIMER .....	XVII
SUMMARY.....	XVIII
<i>SUMMARY TABLE WORLDWIDE PHARMACOGENOMICS MARKET BY</i>	
<i>TECHNOLOGY SEGMENTS, THROUGH 2009 (\$ MILLIONS)</i> .....	XIX
<i>SUMMARY FIGURE WORLDWIDE PHARMACOGENOMICS MARKET BY</i>	
<i>TECHNOLOGY SEGMENTS, 2001-2009 (\$ MILLIONS)</i> .....	XIX
OVERVIEW .....	1
STREAMLINING CLINICAL TRIALS.....	2
TIME FRAME FOR DRUG APPROVAL .....	2
<i>TABLE 1 DRUG DEVELOPMENT AND FDA APPROVAL PROCESS</i> .....	3
HIGH COSTS STIFFLE INNOVATION.....	3
<i>TABLE 2 NME APPROVALS GRANTED BY FDA (UNITED STATES), 1995-2004</i> .....	4
<i>TABLE 3 TOTAL SPENDING ON R&amp;D BY PHARMA COMPANIES, 1999-2003 (\$</i>	
<i>BILLIONS)</i> .....	5
<i>TABLE 4 R&amp;D SPENDING ON CLINICAL DEVELOPMENT BY PHARMA COMPANIES,</i>	
<i>BY DRUG DEVELOPMENT PHASE, 2002 (\$ BILLIONS)</i> .....	5
<i>FIGURE 1 R&amp;D SPENDING ON CLINICAL DEVELOPMENT BY PHARMA</i>	
<i>COMPANIES, BY DRUG DEVELOPMENT PHASE, 2002 (\$ BILLIONS)</i> .....	6
ATTRACTING TRIAL PARTICIPANTS.....	6
PHARMACOGENOMICS AS A SOLUTION.....	7
CAVEATS .....	8
IMPROVING DRUG EFFICACY .....	8
<i>TABLE 5 DRUG INEFFICACY, BY THERAPY TYPE (PERCENTAGE OF PATIENTS</i>	
<i>FAILING TO RESPOND TO THERAPY)</i> .....	9
REDUCING ADVERSE DRUG REACTIONS.....	10
FACTORS CONTRIBUTING TO ADVERSE DRUG	
REACTIONS .....	10
COSTS OF ADVERSE DRUG REACTIONS .....	11
<i>TABLE 6 ADVERSE DRUG REACTIONS IN THE UNITED STATES</i> .....	11
MARKET DRIVERS.....	11
ROLE OF PHARMACOGENOMICS IN ADR PREVENTION .....	12
POST-MARKET DRUG FAILURE .....	12
PROMINENT DRUG WITHDRAWALS .....	13
<i>TABLE 7 PROMINENT DRUGS WITHDRAWALS</i> .....	13
Vioxx.....	13

Rezulin .....	14
Pondimin and Redux .....	14
Seldane.....	15
Posicor .....	15
Baycol (Cerivastatin).....	16
<b>ROLE OF PHARMACOGENOMICS IN REDUCING DRUG</b>	
<b>WITHDRAWALS .....</b>	<b>16</b>
<b>THE SNP CONSORTIUM.....</b>	<b>17</b>
<i>TABLE 8 SNP CONSORTIUM MEMBERS.....</i>	<i>18</i>
<b>THE INTERNATIONAL HAPMAP PROJECT.....</b>	<b>18</b>
<b>PARTICIPANTS IN THE HAPMAP PROJECT .....</b>	<b>19</b>
<i>TABLE 9 HAPMAP PARTICIPANTS AND FUNDING SOURCES.....</i>	<i>20</i>
<i>TABLE 10 STRUCTURE OF THE INTERNATIONAL HAPMAP PROJECT .....</i>	<i>20</i>
<i>TABLE 10 (CONTINUED) .....</i>	<i>21</i>
<b>HAPMAP POPULATIONS AND ETHICAL CONCERNS .....</b>	<b>21</b>
<b>DATA ACCESSIBILITY AND PATENTABILITY .....</b>	<b>22</b>
<b>FOOD AND DRUG ADMINISTRATION: NEW GUIDELINES .....</b>	<b>23</b>
<b>FOOD AND DRUG ADMINISTRATION: NEW GUIDELINES</b>	
<b>(CONTINUED).....</b>	<b>24</b>
<b>SNP IDENTIFICATION MARKET .....</b>	<b>25</b>
<b>SNP IDENTIFICATION MARKET .....</b>	<b>25</b>
<i>TABLE 11 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, THROUGH 2009</i>	
<i>(\$ MILLIONS).....</i>	<i>26</i>
<i>FIGURE 2 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, 2001-2009 (\$</i>	
<i>MILLIONS).....</i>	<i>26</i>
<b>OVERVIEW OF SNP IDENTIFICATION .....</b>	<b>27</b>
<b>STRATEGIES FOR SNP IDENTIFICATION .....</b>	<b>28</b>
<b>CANDIDATE GENE SELECTION .....</b>	<b>28</b>
<b>WHOLE GENOME LINKAGE DISEQUILIBRIUM MAPPING .....</b>	<b>29</b>
<i>TABLE 12 EMERGING TECHNOLOGIES IN WHOLE GENOME MAPPING.....</i>	<i>30</i>
<b>COMBINATION STRATEGIES .....</b>	<b>30</b>
<b>SNP DATABASES .....</b>	<b>30</b>
<i>TABLE 13 MAJOR PRIVATE SNP DATABASES.....</i>	<i>31</i>
<b>COMPUTATIONAL TOOLS FOR SNP IDENTIFICATION .....</b>	<b>31</b>
<b>SNPBROWSER, APPLIED BIOSYSTEMS .....</b>	<b>31</b>
<b>CHROMOSOMBROWSER™, ORCHID BIOSCIENCES .....</b>	<b>32</b>
<b>REALSNP, SEQUENOM.....</b>	<b>32</b>
<b>SNP KNOWLEDGE RESOURCE, ILLUMINA.....</b>	<b>32</b>
<b>CELERA DISCOVERY SYSTEM™, CELERA .....</b>	<b>33</b>
<b>GENOTYPING MARKET .....</b>	<b>34</b>
<b>OVERALL MARKET FOR GENOTYPING TECHNOLOGIES.....</b>	<b>34</b>
<i>TABLE 14 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL,</i>	
<i>THROUGH 2009 (\$ MILLIONS).....</i>	<i>35</i>
<i>FIGURE 3 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL,</i>	
<i>2001-2009 (\$ MILLIONS).....</i>	<i>35</i>

GENOTYPING TECHNOLOGY OVERVIEW.....	36
ALLELIC DISCRIMINATION BY DNA POLYMERASES.....	37
TABLE 15 COMPARATIVE ADVANATAGES OF ALLELIC DISCRIMINATION	
METHODS.....	37
SINGLE-BASE EXTENSION.....	37
ALLELE-SPECIFIC EXTENSION.....	38
PYROSEQUENCING.....	38
STRUCTURE-SPECIFIC CLEAVAGE.....	39
TAQMAN ASSAY.....	39
TABLE 16 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY	
TYPE, THROUGH 2009 (\$ MILLIONS).....	40
FIGURE 4 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY	
TYPE, 2001-2009 (\$ MILLIONS).....	40
ALLELIC DISCRIMINATION BY HYBRIDIZATION.....	41
MICROARRAYS FOR GENOTYPING.....	42
TABLE 17 TOTAL GLOBAL MICROARRAY MARKET AND THAT FOR GENOTYPING	
APPLICATIONS, THROUGH 2009 (\$ MILLIONS).....	43
EMERGING TECHNOLOGY FOR ALLELIC DISCRIMINATION BY	
DNA LIGASES.....	44
DETECTION OF ALLELE-SPECIFIC PRODUCTS.....	44
TABLE 18 COMPARATIVE ADVANATAGES OF DETECTION METHODS.....	45
MASS SPECTROMETRY.....	45
TABLE 19 STRENGTHS AND WEAKENESSES OF MASS SPECTROMETRY FOR	
GENOTYPING.....	46
New Developments in Mass Spectrometry for DNA	
Analysis.....	46
TABLE 20 EMERGING TECHNOLOGIES IN DNA MASS SPECTROMETRY.....	47
FLUORESCENCE RESONANCE ENERGY TRANSFER.....	47
FLUORESCENCE POLARIZATION.....	48
LENGTH-BASED DETECTION SYSTEMS.....	48
TABLE 21 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY	
TYPE, THROUGH 2009 (\$ MILLIONS).....	49
FIGURE 5 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY	
TYPE, 2001-2009 (\$ MILLIONS).....	49
Length-based Detection Systems (continued).....	50
COMPARISON OF COST AND THROUGHPUT.....	51
TABLE 22 COMPARISON OF GENOTYPING PLATFORMS COST AND	
THROUGHPUT.....	51
PHARMACOGENOMICS DIAGNOSTICS MARKET.....	52
OVERALL MARKET FOR PHARAMCOGENOMICS DIAGNOSTICS.....	52
TABLE 23 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS BY	
TYPE, THROUGH 2009 (\$ MILLIONS).....	52
FIGURE 6 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS	
BY TYPE, 2001-2009 (\$ MILLIONS).....	53
MICROARRAYS.....	54
TECHNOLOGY OVERVIEW.....	54
PLANAR DNA MICROARRAYS.....	54

<i>TABLE 24 MAJOR SUPPLIERS OF PLANAR DNA MICROARRAYS</i> .....	55
<i>TABLE 24 (CONTINUED)</i> .....	56
ELECTRONIC MICROARRAYS .....	56
Nanochip (Nanogen, San Diego) .....	56
BEAD MICROARRAYS .....	57
EMERGING TECHNOLOGY: NANOPARTICLE ARRAYS.....	57
Verigene (Nanosphere, Chicago, IL) .....	57
Nanoplex Technologies (Mountain View, CA).....	58
<i>TABLE 25 MAJOR SUPPLIERS OF BEAD MICROARRAYS</i> .....	58
MARKET FOR MICROARRAYS IN PHARMACOGENOMICS .....	58
MARKET FOR MICROARRAYS IN PHARMACOGENOMICS.....	59
<i>TABLE 26 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, THROUGH 2009 (MILLIONS \$)</i> .....	59
<i>FIGURE 7 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, 2001-2009 (MILLIONS \$)</i> .....	60
PCR-BASED ASSAYS .....	61
<i>TABLE 27 MAJOR SUPPLIERS OF PCR-BASED ASSAYS</i> .....	61
PCR-BASED TECHNOLOGIES.....	62
LightCycler (Roche Molecular Systems, Pleasanton, CA) .....	62
TaqMan DNA probes (Applied Biosystems, Foster City, CA) .....	62
Invader (Third Wave Technologies, Madison, WI).....	63
Tag-It Mutation Assay (Tm Bioscience) .....	64
<i>TABLE 28 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, THROUGH 2009 (\$ MILLIONS)</i> .....	64
<i>FIGURE 8 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, 2001-2009 (\$ MILLIONS)</i> .....	65
<i>IN SITU</i> ANALYSIS .....	66
TECHNOLOGY .....	66
HER2 FISH TESTING.....	67
COMPARISON WITH IHC.....	68
<i>TABLE 29 COMPARISON OF FISH AND IHC TESTING FOR HER2</i> .....	68
<i>TABLE 30 GLOBAL MARKET FOR IN SITU ASSAYS IN PHARMACOGENOMICS OF BREAST CANCER, THROUGH 2009 (\$ MILLIONS)</i> .....	69
PHARMACOGENOMIC THERAPEUTICS BY DISEASE.....	70
CARDIOVASCULAR DISEASE.....	70
HEART FAILURE.....	71
Angiotensin I-Converting Enzyme (ACE) .....	71
BiDil .....	71
Projected Market for BiDil .....	72
<i>TABLE 31 PROJECTED BIDIL® MARKET, THROUGH 2009 (\$ MILLIONS)</i> .....	72
HYPERCHOLESTOLEMIA .....	73
<i>TABLE 32 MAJOR PRODUCERS OF STATINS</i> .....	74
Mechanism of Statins .....	74
Individual Variation Affects Statin Efficacy .....	75
STRENGTH Clinical Study of Statins.....	75

BREAST CANCER.....	76
BREAST CANCER AND HER2.....	77
Regulatory Guidelines.....	78
Emerging Herceptin Combination Market.....	78
<i>TABLE 33 GLOBAL MARKET FOR HERCEPTIN, BY REGION, THROUGH 2009 (\$</i>	
<i>MILLIONS)</i> .....	79
LEUKEMIA.....	80
CHRONIC MYELOID LEUKEMIA (CML).....	80
Genetic Marker of CML.....	81
Gleevec.....	81
<i>TABLE 34 GLOBAL MARKET FOR GLEEVEC/GLIVEC, BY REGION, THROUGH 2009</i>	
<i>(\$ MILLIONS)</i> .....	82
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).....	83
ACUTE MYELOID LEUKEMIA (AML).....	84
LUNG CANCER.....	85
NON-SMALL CELL LUNG CANCER.....	85
Clinical Studies on Iressa.....	86
Fast Track Approval in the US.....	86
Fast Track Approval in Japan.....	87
Post-Market Studies of Iressa.....	88
<i>TABLE 35 GLOBAL SALES OF IRESSA PRIOR TO FDA ANNOUNCEMENT, 2002-</i>	
<i>2004 (\$ MILLIONS)</i> .....	88
ASTHMA.....	89
GENETIC VARIANTS AFFECTING ASTHMA THERAPY.....	90
<i>TABLE 36 GENES OF INTEREST IN THE PHARMACOGENOMICS OF ASTHMA</i> .....	90
MAJOR PLAYERS AND DEVELOPMENTS.....	90
<i>TABLE 37 MAJOR PLAYERS IN PHARMACOGENOMICS OF ASTHMA TREATMENT</i> .....	91
<i>TABLE 38 GLOBAL MARKET FOR ASTHMA THERAPIES, BY TYPE, THROUGH 2009</i>	
<i>(\$ MILLIONS)</i> .....	92
PHARMACOGENOMICS OF HIV/AIDS.....	93
VIRAL RESISTANCE.....	93
GENETIC RESISTANCE TESTING.....	94
<i>TABLE 39 MAJOR SUPPLIERS OF HIV GENOTYPIC RESISTANCE TESTS</i> .....	95
<i>TABLE 40 GLOBAL MARKET FOR HIV RESISTANCE TESTING BY REGION,</i>	
<i>THROUGH 2009 (\$ MILLIONS)</i> .....	95
Education Gap.....	96
ABACAVIR, A PHARMACOGENOMICS SUCCESS STORY.....	97
<i>TABLE 41 GLOBAL MARKET FOR ABACAVIR, BY REGION, THROUGH 2009 (\$</i>	
<i>MILLIONS)</i> .....	98
<i>FIGURE 9 GLOBAL MARKET FOR ABACAVIR, BY REGION, 2000-2009 (\$</i>	
<i>MILLIONS)</i> .....	98
Abacavir, a Pharmacogenomics Success Story (continued).....	99
PHARMACOGENOMICS OF DRUG METABOLISM.....	100
DRUG METABOLISM BY CYTOCHROMES.....	100
P450 ISOZYMES AND PHARMACEUTICALS.....	101
<i>TABLE 42 MAJOR CYTOCHROME P450 ISOZYMES</i> .....	102
P450 Isozyme CYP3A.....	102

P450 Isozyme CYP2D6.....	103
P450 Isozyme CYP2C9 .....	103
P450 Isozyme 2C19.....	104
P450 Isozyme 1A2.....	104
P450 DIAGNOSTIC TESTING .....	104
TABLE 43 GLOBAL MARKET FOR AMPLICHIP ARRAYS IN DIAGNOSTIC USE BY REGION, THROUGH 2009 (\$ MILLIONS).....	105
P450 TESTING FOR RESEARCH PURPOSES.....	106
TABLE 44 MAJOR SUPPLIERS OF CYTOCHROME P450 TESTING FOR RESEARCH PURPOSES.....	106
COMPETITION WITH PHENOTYPIC ASSAYS .....	107
TECHNOLOGY .....	108
PATENTS AND COMMERCIALIZATION ISSUES .....	108
PATENT ANALYSIS .....	108
PATENT SHARE BY APPLICATION TYPE .....	109
TABLE 45 PHARAMCOGENOMICS PATENTS BY TECHNOLOGY, 2004.....	109
TABLE 46 PHARAMCOGENOMICS PATENTS BY DISEASE TARGET, 2004.....	109
PATENT SHARE BY REGION .....	110
TABLE 47 PHARMACOGONOMICS PATENTS BY REGION, 2004.....	110
TABLE 48 PHARMACOGONOMICS PATENTS BY ASSIGNEE, JANUARY 2004- JANUARY 2005 .....	111
INDUSTRY STRUCTURE .....	112
DRUG MARKET SEGMENTATION .....	112
MAJOR PHARMACOGONOMICS COMPANIES.....	113
TABLE 49 MAJOR PHARMACOGONOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 (\$ MILLIONS).....	113
TABLE 49 (CONTINUED) .....	114
FIGURE 10 MAJOR PHARMACOGONOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 (%).....	114
COLLABORATIONS .....	115
TABLE 50 KEY COLLABORATIONS IN THE PHARMACOGONOMICS INDUSTRY.....	115
MYRIAD/ABBOTT .....	115
CURAGEN/PFIZER .....	116
DECODE/MERCK.....	116
DECODE/ROCHE .....	117
MILLENIUM/BAYER .....	117
ORCHID BIOSCIENCES/U.K. GOVERNMENT .....	117
LYNX/INSTITUTE FOR SYSTEMS BIOLOGY .....	117
NOVARTIS/CELERA.....	118
THIRD WAVE/RIKEN .....	118
IMPACT OF RELATED INDUSTRIES .....	118
NANOTECHNOLOGY .....	118
BIOINFORMATICS .....	119
ANALYSIS OF SUCCESSFUL COMPANIES .....	119
NOVARTIS — GLEEVEC/GLIVEC .....	120

Disease Target .....	120
Rapid Movement Through Trials.....	120
Orphan Drug Approval.....	120
Strong Brand Recognition .....	121
Continued Studies Identify New Target Populations .....	121
AFFYMETRIX, SANTA CLARA, CA .....	122
Marketing .....	122
Technical Support.....	123
Strategic Positioning .....	123
First Mover Status Maintained .....	124
Intellectual Property .....	124
INTERNATIONAL ASPECTS .....	125
UNITED STATES .....	125
CENTRALIZED PHARMGKB DATABASE .....	125
FUNDING INITIATIVES .....	125
EUROPEAN UNION .....	126
NEW DRUG APPROVALS AND INNOVATION .....	126
R&D SPENDING IN THE EUROPEAN UNION.....	126
SOCIAL FACTORS .....	127
REGULATORY ENVIRONMENT.....	127
CHEAPER CLINICAL TRIALS .....	128
MIGRATION TO THE U.S. ....	128
JAPAN.....	129
NEW DRUG APPROVALS AND INNOVATION .....	129
REGULATORY ENVIRONMENT.....	129
LIMITED ACADEMIC-INDUSTRY COLLABORATION.....	130
VENTURE CAPITAL.....	130
OTHER GEOGRAPHIC AREAS .....	131
INTELLECTUAL PROPERTY .....	131
Intellectual Property (continued).....	132
ETHICAL CONSIDERATIONS.....	133
GENETIC EXCEPTIONALISM .....	133
PRIVACY.....	133
DEVELOPING NATIONS.....	133
DISCRIMINATION .....	134
GENES AND ENVIRONMENT .....	135
IMPLICATIONS FOR THE FUTURE OF HEALTH CARE .....	136
EDUCATED DECISION-MAKING .....	136
RESPONSIBILITY FOR FAILURES.....	137
OVER-THE-COUNTER TESTS .....	137
DEFINITION OF ORPHAN DRUGS.....	137
DEFINITION OF ORPHAN DRUGS (CONTINUED) .....	138

COMPANY PROFILES .....	139
ABBOTT LABORATORIES, ABBOTT PARK, IL .....	139
AMERSHAM (NOW GE HEALTHCARE), BUCKINGHAMSHIRE, UK.....	139
APPLERA CORPORATION, NORWALK, CT.....	140
ASTRAZENECA, ALDERLEY PARK, UK .....	141
CURAGEN CORPORATION, NEW HAVEN, CT .....	141
DAKOCYTOMATION, COPENHAGEN, DENMARK .....	142
DECODE GENETICS, REYKJAVIK, ICELAND.....	143
DXS, MANCHESTER, UK .....	143
ERAGEN, MASDISON, WI .....	144
FIVEPRIME THERAPEUTICS, SAN FRANCISCO, CA .....	144
GENAISSANCE PHARMACEUTICALS, NEW HAVEN, CT .....	145
GENENTECH, SOUTH SAN FRANCISCO, CA.....	146
GENTRIS, MORRISVILLE, NC.....	146
GLAXOSMITHKLINE, BRENTFORD, UK.....	147
HUMAN GENOME SCIENCES, ROCKVILLE, MD .....	147
ILLUMINA, SAN DIEGO, CA.....	148
INCYTE, PALO ALTO, CA.....	149
INTERLEUKIN GENETICS, WALTHAM, MA .....	150
LUMINEX CORP., AUSTIN, TX.....	150
MERCK, WHITEHOUSE STATION, NJ .....	151
MILLENIUM PHARMACEUTICALS, CAMBRIDGE, MA .....	151
MYRIAD GENETICS, INC., SALT LAKE CITY, UT.....	151
NANOGEN, SAN DIEGO, CA.....	152
NANOSPHERE, NORTHBROOK, IL.....	152
NITROMED, LEXINGTON, MA.....	153
ORCHID BIOSCIENCES, PRINCETON, NJ .....	153
PHARMASEQ, MONMOUTH JUNCTION, NJ .....	154
ROCHE (F. HOFFMANN-LA ROCHE LTD), BASEL, SWITZERLAND.....	155
SEQUENOM, SAN DIEGO, CA.....	155
THIRD WAVE, MADISON, WI.....	156
TM BIOSCIENCE CORP., TORONTO, ON, CANADA .....	156
WYETH, MADISON, NJ .....	157